8-K: Aeternum Health Completes Merger, Shifts Focus to Longevity

Aeternum Health, Inc. (formerly Shorepower Technologies, Inc.) announced the completion of its merger with Aeternum Health LLC, marking a strategic pivot towards longevity and healthspan optimization.

Summary

• Aeternum Health, Inc. (formerly Shorepower Technologies, Inc.) has completed its merger with Aeternum Health LLC, effective June 30, 2026.
• The company is divesting its transportation electrification business to focus on critical minerals mining and longevity/anti-aging healthcare solutions.
• Paul Mann has been appointed President, CEO, and sole director, replacing Jeff Kim, who resigned from these roles.
• The merger involved the issuance of 49,000,000 shares of common stock (51% ownership) and 2,000,000 shares of Series B preferred stock to the sole member of Aeternum Health LLC.
• Aeternum Health LLC contributed assets including intellectual property related to a peptide-based longevity treatment, at least $1.5 million in cash, and a related commercialization business.
• The company's authorized shares were increased from 100 million to 250 million.
• As of June 30, 2026, the company had 96,105,204 shares of common stock and 2,000,000 shares of Series B preferred stock outstanding.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's precarious financial position, lack of operating history, significant accumulated deficit, and substantial forward-looking risks, despite the strategic pivot.

Positives

• Completion of a merger that realigns the company's strategic focus towards the potentially high-growth longevity and critical minerals sectors.
• Appointment of new leadership with experience in healthcare investments and biotechnology.
• Securing assets including intellectual property and data for a peptide-based longevity treatment.
• The company is seeking to leverage government support programs for critical minerals development.
• Increased authorized shares provide flexibility for future capital raises and strategic initiatives.

Negatives

• The company has an extremely limited operating history and no current sales, raising substantial doubt about its ability to continue as a going concern.
• Significant accumulated deficit of $(8,388,144) as of March 31, 2026 (pro forma combined).
• The company has a very small employee base (one full-time employee as of July 1, 2026).
• The company's common stock is subject to penny stock rules, potentially limiting liquidity and investor access.
• The company will require substantial additional funding to implement its business plan.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's board of directors has no independent members.
• The company has no audit, nominating, or governance committees; the full board performs these functions.

Risks

• Extremely limited operating history and no current sales, with substantial doubt about the ability to continue as a going concern.
• Need for significant additional capital to fund business plan, with no assurance of availability on favorable terms.
• Potential for substantial dilution to existing stockholders from future equity financings.
• Inability to manage potential growth effectively, which could strain management, operational, and financial resources.
• Subject to penny stock rules, which may restrict broker-dealer activity and investor ability to sell shares.
• Dependence on the successful development and commercialization of longevity products and mining of critical minerals.
• Intense competition in both critical minerals mining and longevity product development.
• Fluctuations in demand for and prices of critical minerals.
• Potential for political, trade, and regulatory developments to adversely affect financial condition.
• Uncertainty in estimates of critical mineral reserves.
• Challenges in obtaining necessary permits and complying with extensive environmental regulations for mining operations.
• Uncertainty regarding the regulatory pathway for longevity products with the FDA.
• Potential for adverse side effects or lack of efficacy in longevity product development.
• Failure to protect intellectual property rights.
• Cybersecurity threats and potential disruptions to operations.
• The company's financial status raises doubt about its ability to continue as a going concern.
• The concentration of ownership with Paul Mann could prevent new investors from influencing significant corporate decisions.

Future Outlook

The company intends to focus on mining critical minerals and developing longevity and anti-aging healthcare solutions. This strategic shift requires significant capital investment and faces considerable risks due to the company's early stage and lack of operating history.

Management Comments

• Management intends to fund operations through additional capital contributions, debt financing, strategic partnerships, and the consummation of the proposed merger transaction.
• Management believes that equity grants provide executives with a strong link to long-term performance, create an ownership culture, and align interests with stockholders.
• Management believes that its compensation programs do not encourage inappropriate actions or risk-taking by executive officers.

Industry Context

StockSavvy.ai notes that the pivot to longevity and critical minerals reflects current market trends, with significant government interest in securing domestic supply chains for critical minerals and growing investment in the healthspan and anti-aging sectors. However, the company's lack of operating history and substantial financial challenges present significant hurdles.

Comparison to Industry Standards

• The company's lack of independent directors and board committees deviates from standard corporate governance practices for publicly traded companies.
• The company's reliance on a single director (Paul Mann) for all board functions is not aligned with industry best practices for robust oversight.
• The company's current financial state, with minimal assets and significant accumulated deficit, is not comparable to established companies in the biotechnology or mining sectors.

Management Changes

Corporate Governance

Related Party Transactions

• Promissory note to Jeff Kim for $200,000 issued February 15, 2022, with a balance due of $0 and accrued interest of $18,817 as of December 31, 2025.
• Promissory note to Jeff Kim for $253,954 issued March 1, 2022, with a principal balance due of $207,854 and accrued interest of $40,223 as of December 31, 2025.
• Promissory note to Jeff Kim for $1,237,600 issued December 31, 2022 (after $400,000 forgiveness), with a principal balance due of $837,600 and accrued interest of $156,974 as of December 31, 2025.
• Jeff Kim's annual base salary is $200,000, subject to cash flow availability, with accrued compensation due of $506,668 as of December 31, 2025.
• Amounts payable to Jeff Kim for operating expenses paid on behalf of the company were $48,864 as of December 31, 2025.
• Consulting agreement with Paul Mann for corporate development, business strategy, and fundraising services at $10,000 per month, with $30,000 recognized as expense for the period ended March 31, 2026.
• Promissory note issued to Paul Mann on December 31, 2025, for $40,348.
• Promissory note issued to Paul Mann on March 31, 2026, for $32,000.
• Promissory note issued to Paul Mann on April 20, 2026, for $50,000.
• Promissory note issued to Paul Mann on May 18, 2026, for $500,000.
• Promissory note issued to Paul Mann on May 19, 2026, for $700,000.
• Promissory note issued to Paul Mann on May 21, 2026, for $248,000.

Stakeholder Impact

• Existing shareholders may experience significant dilution due to future capital raises.
• Investors face substantial risks due to the company's early stage, lack of revenue, and going concern issues.
• Employees (currently one full-time) may face uncertainty given the company's financial condition and strategic pivot.
• Creditors and lenders may face increased risk given the company's current liquidity and need for future financing.

Next Steps

• Focus on mining critical minerals.
• Develop services, products, and solutions to increase longevity and achieve optimal health.
• Secure additional funding to support business plan execution.
• Implement operational and financial systems, procedures, and controls to manage potential growth.
• Hire additional personnel, including salespeople.
• Develop and implement an executive compensation program for Q3 2026 and beyond.

Key Dates

Recommendation

The company's dire financial situation, lack of operating history, significant accumulated deficit, and the substantial risks associated with its new ventures in critical minerals and longevity healthcare, coupled with material weaknesses in internal controls, make it a highly speculative investment with a high probability of failure. The need for substantial future capital raises further exacerbates the risk of dilution and financial distress.

Keywords

Aeternum Health, Shorepower Technologies, Merger, Longevity, Critical Minerals, Healthcare, Biotechnology, Corporate Governance, SEC Filing, Form 8-K